You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CML-BP

Showing 1 - 25 of 1,624
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001, BP1001

Completed
  • Recurrent Adult Acute Myeloid Leukemia
  • +3 more
  • BP1001
  • BP1001 in combination with LDAC
  • Houston, Texas
    M. D. Anderson Cancer Center
May 26, 2020

Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001 (varying

Withdrawn
  • Chronic Myelogenous Leukemia, Ph1-Positive
  • +2 more
  • BP1001 (varying dose)
  • +2 more
  • Houston, Texas
    The University of Texas M.D. Anderson Cancer Center
May 26, 2020

Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C) Trial in Worldwide (Vodobatinib (K0706) capsules)

Recruiting
  • Healthy (For Part A)
  • Chronic Myeloid Leukemia (for Part B and C)
  • Vodobatinib (K0706) capsules
  • Downey, California
  • +69 more
Dec 7, 2022

3rd Line Therapy or More to Treat Adult CML- CP in Real World

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Oct 16, 2023

CML Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Active, not recruiting
  • Chronic Myeloid Leukemia
    • Saint-Pierre, Reunion, France
    • +39 more
    Dec 13, 2021

    CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

    Not yet recruiting
    • CML, Chronic Phase
    • Harbin, Heilongjiang, China
      Institute of Hematology and Oncology, Harbin The First Hospital
    May 5, 2022

    Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Uijeongbu si (Asciminib single agent, Asciminib, Imatinib)

    Recruiting
    • Chronic Myelogenous Leukemia
    • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    • Asciminib single agent
    • +5 more
    • Ann Arbor, Michigan
    • +49 more
    Jan 26, 2023

    Leukemia Trial in Worldwide (Dasatinib)

    Active, not recruiting
    Has Results
    • Leukemia
    • Birmingham, Alabama
    • +173 more
    Dec 1, 2022

    Chronic Myeloid Leukemia Trial in Worldwide

    Recruiting
    • Chronic Myeloid Leukemia
      • Montréal, Quebec, Canada
      • +25 more
      Jul 25, 2022

      Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia Trial in Worldwide

      Recruiting
      • Acute Myeloid Leukemia
      • +8 more
      • Ghent, Belgium
      • +28 more
      Nov 11, 2022

      CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

      Completed
      • Chronic Phase Chronic Myelogenous Leukemia
      • +3 more
        • Limerick, Dooradoyle, Ireland
        • +32 more
        Aug 13, 2021

        Chronic Myelogenous Leukemia Trial in Worldwide (Dasatinib)

        Active, not recruiting
        • Chronic Myelogenous Leukemia
        • Amman, Jordan
        • +4 more
        Jan 17, 2022

        Myeloid Leukemia, Chronic, Chronic Phase Trial in Worldwide (Ponatinib)

        Active, not recruiting
        Has Results
        • Myeloid Leukemia, Chronic, Chronic Phase
        • Atlanta, Georgia
        • +85 more
        Jan 4, 2022

        Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia Trial in Worldwide (Ponatinib)

        Completed
        Has Results
        • Chronic Myeloid Leukemia
        • Ph+ Acute Lymphoblastic Leukemia
        • St Leonards, New South Wales, Australia
        • +41 more
        Jan 18, 2021

        Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)

        Terminated
        Has Results
        • Chronic Phase Chronic Myeloid Leukemia
        • Ponatinib 30 mg QD
        • +2 more
        • Bruxelles, Belgium
          Cliniques Universitaire Saint-Luc (Site 058)
        Oct 28, 2021

        Vascular Occlusive Events Associated With ICLUSIG®

        Terminated
        • Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
          • Hackensack, New Jersey
          • +1 more
          Oct 30, 2020

          Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs

          Not yet recruiting
          • Myeloproliferative Neoplasms (MPNs)
          • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
          • (no location specified)
          Mar 24, 2023

          Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

          Completed
          • Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase
          • Cairo, Egypt
            National Cancer Institute (NCI)
          Feb 22, 2021

          Chronic Phase Chronic Myeloid Leukemia Trial in Worldwide (Dasatinib)

          Completed
          Has Results
          • Chronic Phase Chronic Myeloid Leukemia
          • Duarte, California
          • +27 more
          Dec 7, 2021

          Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase

          Terminated
          • Accelerated Phase Chronic Myelogenous Leukemia (CML)
          • +3 more
          • Houston, Texas
            M D Anderson Cancer Center
          Nov 17, 2020

          Concomitant Medications at CML Diagnosis

          Completed
          • Chronic Myeloid Leukemia
          • the prevalence of comorbid conditions
          • (no location specified)
          Sep 16, 2023

          Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia Trial

          Completed
          • Chronic Phase Chronic Myeloid Leukemia
          • +4 more
          • Toronto, Ontario, Canada
            Princess Margaret Hospital / University Health Network
          Oct 29, 2020

          Hypertension Trial in San Francisco (BP Activate Letter, Control Letter)

          Active, not recruiting
          • Hypertension
          • BP Activate Letter
          • Control Letter
          • San Francisco, California
            University of California, San Francisco
          Nov 21, 2023

          Metabolic Alternation and Clinicohematological Characteristic in

          Not yet recruiting
          • CML, Chronic Phase
          • Tyrosine kinase inhibitor
          • (no location specified)
          Nov 6, 2023